Summit Trail Advisors LLC Makes New Investment in Insulet Co. (NASDAQ:PODD)

Summit Trail Advisors LLC bought a new position in shares of Insulet Co. (NASDAQ:PODD) during the fourth quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The institutional investor bought 1,882 shares of the medical instruments supplier’s stock, valued at approximately $491,000.

Several other institutional investors have also recently made changes to their positions in PODD. Blue Trust Inc. lifted its position in Insulet by 84.1% during the 3rd quarter. Blue Trust Inc. now owns 127 shares of the medical instruments supplier’s stock valued at $30,000 after acquiring an additional 58 shares during the period. Venturi Wealth Management LLC increased its stake in shares of Insulet by 633.3% during the third quarter. Venturi Wealth Management LLC now owns 154 shares of the medical instruments supplier’s stock valued at $36,000 after purchasing an additional 133 shares in the last quarter. TD Private Client Wealth LLC lifted its holdings in shares of Insulet by 32.6% during the third quarter. TD Private Client Wealth LLC now owns 228 shares of the medical instruments supplier’s stock valued at $53,000 after purchasing an additional 56 shares during the last quarter. Friedenthal Financial bought a new stake in shares of Insulet in the 4th quarter worth approximately $57,000. Finally, Versant Capital Management Inc grew its stake in shares of Insulet by 106.1% in the 4th quarter. Versant Capital Management Inc now owns 305 shares of the medical instruments supplier’s stock worth $80,000 after buying an additional 157 shares during the last quarter.

Insider Buying and Selling at Insulet

In other news, CAO Lauren Budden sold 915 shares of the company’s stock in a transaction dated Tuesday, December 10th. The shares were sold at an average price of $275.62, for a total transaction of $252,192.30. Following the completion of the sale, the chief accounting officer now owns 5,733 shares of the company’s stock, valued at $1,580,129.46. This represents a 13.76 % decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through this link. Also, EVP Eric Benjamin sold 12,394 shares of the firm’s stock in a transaction that occurred on Tuesday, January 21st. The stock was sold at an average price of $280.00, for a total transaction of $3,470,320.00. Following the completion of the transaction, the executive vice president now directly owns 11,383 shares in the company, valued at approximately $3,187,240. The trade was a 52.13 % decrease in their position. The disclosure for this sale can be found here. Company insiders own 0.47% of the company’s stock.

Wall Street Analysts Forecast Growth

A number of research analysts have issued reports on PODD shares. Canaccord Genuity Group lifted their price objective on Insulet from $269.00 to $304.00 and gave the company a “buy” rating in a research note on Monday, December 9th. TD Cowen raised their price target on Insulet from $264.00 to $324.00 and gave the company a “buy” rating in a report on Friday, January 3rd. Wells Fargo & Company upped their price target on shares of Insulet from $290.00 to $305.00 and gave the stock an “overweight” rating in a research note on Wednesday, December 11th. JPMorgan Chase & Co. raised their price objective on shares of Insulet from $280.00 to $330.00 and gave the company an “overweight” rating in a research note on Thursday, December 12th. Finally, Sanford C. Bernstein began coverage on shares of Insulet in a report on Wednesday, November 6th. They issued an “outperform” rating and a $300.00 target price for the company. Two investment analysts have rated the stock with a hold rating and thirteen have assigned a buy rating to the stock. Based on data from MarketBeat.com, Insulet currently has an average rating of “Moderate Buy” and a consensus price target of $277.13.

Insulet Stock Down 0.4 %

Shares of Insulet stock opened at $284.26 on Wednesday. Insulet Co. has a twelve month low of $160.19 and a twelve month high of $289.46. The company has a quick ratio of 2.80, a current ratio of 3.68 and a debt-to-equity ratio of 1.21. The company’s 50 day moving average is $270.94 and its 200 day moving average is $242.89. The company has a market cap of $19.94 billion, a price-to-earnings ratio of 48.67, a price-to-earnings-growth ratio of 3.61 and a beta of 1.23.

Insulet Company Profile

Insulet Corporation develops, manufactures, and sells insulin delivery systems for people with insulin-dependent diabetes. The company's Omnipod platform includes the Omnipod 5 Automated Insulin Delivery System (Omnipod 5) which includes a proprietary AID algorithm embedded in the Pod that integrates with a third-party continuous glucose monitor to obtain glucose values through wireless bluetooth communication; Omnipod DASH that features a bluetooth enabled Pod that is controlled by a smartphone-like Personal Diabetes Manager with a color touch screen user interface; and Omnipod GO, a standalone, wearable, insulin delivery system that provides a fixed rate of continuous rapid-acting insulin for 72 hours.